Investors cheer as two coronavirus vaccine candidates report T-cell responses, but findings are still early stage

Investors cheer as two coronavirus vaccine candidates report T-cell responses, but findings are still early stage (marketwatch.com)

Investors cheer as two coronavirus vaccine candidates report T-cell responses, but findings are still early stage

This is the first time that investigational COVID-19 vaccines have been reported to have a T-cell response

At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a more durable form of immunity than an antibody response.

Read the complete article on marketwatch.com

Submitted by mo2 on Mon, 07/20/2020 - 00:09